EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target

Bo Yang, Yueyang Yan, Dongqiang Wang, Ying Zhang, Jigang Yin, Guan Zhu iD

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Bo Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Zoonotic Diseases, Key Laboratory of Zoonosis Research of the Ministry of Education, the Institute of Zoonosis, and the Coll…. Hauptthemen laut MEDLINE: Cryptosporidium parvum, Cryptosporidiosis, Parasites, Cryptosporidium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cryptosporidium parvum is a globally distributed zoonotic protozoan parasite that causes moderate to severe, sometime deadly, watery diarrhea in humans and animals, for which fully effective treatments are yet unavailable. In studying the mechanism of action of drugs against intracellular pathogens, it is important to validate whether the observed anti-infective activity is attributed to the drug action on the pathogen or host target. For the epicellular parasite Cryptosporidium , we have previously developed a concept that the host cells with significantly increased drug tolerance by transient overexpression of the multidrug resistance protein-1 (MDR1) could be utilized to evaluate whether and how much the observed anti-cryptosporidial activity of an inhibitor was attributed to the inhibitor’s action on the parasite target. However, the transient transfection model was only applicable to evaluating native MDR1 substrates. Here we report an advanced model using stable MDR1-transgenic HCT-8 cells that allows rapid development of novel resistance to non-MDR1 substrates by multiple rounds of drug selection. Using the new model, we successfully validated that nitazoxanide, a non-MDR1 substrate and the only FDA-approved drug to treat human cryptosporidiosis, killed C . parvum by fully (100%) acting on the parasite target. We also confirmed that paclitaxel acted fully on the parasite target, while several other inhibitors including mitoxantrone, doxorubicin, vincristine and ivermectin acted partially on the parasite targets. Additionally, we developed mathematical models to quantify the proportional contribution of the on-parasite-target effect to the observed anti-cryptosporidial activity and to evaluate the relationships between several in vitro parameters, including antiparasitic efficacy ( EC i ), cytotoxicity ( TC i ), selectivity index ( SI ) and Hill slope ( h ). Owning to the promiscuity of the MDR1 efflux pump, the MDR1 -transgenic host cell model could be applied to assess the on-parasite-target effects of newly identified hits/leads, either substrates or non-substrates of MDR1, against Cryptosporidium or other epicellular pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cryptosporidium parvumCryptosporidiosisParasitesCryptosporidiumAnimalsHumansPaclitaxelATP Binding Cassette Transporter, Subfamily B, Member 1AlgorithmsNitro CompoundsThiazoles

Substanzen

PaclitaxelATP Binding Cassette Transporter, Subfamily B, Member 1nitazoxanideNitro CompoundsThiazoles

Autor:innen und Institutionen

  • State Key Laboratory for Zoonotic Diseases, Key Laboratory of Zoonosis Research of the Ministry of Education, the Institute of Zoonosis, and the College of Veterinary Medicine, Jilin University, Changchun, China.

ORCID-Profile: Guan Zhu

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China

Zitieren

APA

Yang, B., Yan, Y., Wang, D., Zhang, Y., Yin, J., & Zhu, G. (2023). On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011217

Vancouver

Yang B, Yan Y, Wang D, Zhang Y, Yin J, Zhu G. On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011217

BibTeX
@article{Yang2023,
  author = {Yang, Bo and Yan, Yueyang and Wang, Dongqiang and Zhang, Ying and Yin, Jigang and Zhu, Guan},
  title = {On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011217}
}
Kostenlos starten →